Novartis' Greek subsidiary agreed to pay a criminal penalty of $225 million, while Novartis itself agreed to pay more than $112 million in disgorgement and interest, representing the amount of illicit profits. In addition, the Greek subsidiary entered a three-year deferred prosecution agreement with the DOJ. Alcon admitted that it conspired to violate the FCPA by creating false books and records to hide alleged bribery schemes and other misconduct, according to the DOJ and the SEC, paid a separate criminal penalty of $8.9 million and also entered into a deferred prosecution agreement. In addition to paying the fines and penalties, both companies have agreed to enhance their compliance programs and file update reports on their efforts.